The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells

  • Kelden Richardson
  • , Simon P. Keam
  • , Joe Jiang Zhu
  • , Deborah Meyran
  • , Criselle D’Souza
  • , Sean Macdonald
  • , Kerry Campbell
  • , Michael Robbins
  • , Natalie A. Bezman
  • , Kirsten Todd
  • , Hang Quach
  • , David S. Ritchie
  • , Simon J. Harrison
  • , H. Miles Prince
  • , Joseph A. Trapani
  • , Misty R. Jenkins
  • , Paul A. Beavis
  • , Phillip K. Darcy
  • , Paul J. Neeson

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Fingerprint

Dive into the research topics of 'The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells'. Together they form a unique fingerprint.

Immunology and Microbiology